Top

Published in:

Open Access 01-01-2019 | Review

Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature

Authors: Beata Polkowska-Pruszyńska, Agnieszka Gerkowicz, Paulina Szczepanik-Kułak, Dorota Krasowska

Published in: Archives of Dermatological Research | Issue 1/2019

Abstract

Systemic sclerosis (SSc) is a chronic, connective tissue disease with an autoimmune pattern characterized by inflammation, fibrosis and microcirculation changes leading to internal organs malfunctions. Recently, the presence of uncharacteristic gastrointestinal symptoms in the course of SSc has been underlined. The possible cause of such clinical presentation is the small intestinal bacterial overgrowth (SIBO). Nevertheless, these manifestations resulting from gastrointestinal tract hypomotility may occur in numerous disease entities. The systematic review of the literature was performed on MEDLINE database using the relevant MeSH terms including all sub-headings. After further investigation, the initial number of 56 records was limited to 7 results. The study analysis showed an increased presence of SIBO in 39% of patients suffering from SSc. The average SSc duration was longer in SSc patients with coexisting SIBO. SIBO remains a diagnostic and therapeutic challenge and therefore is a significant clinical problem among patients suffering from SSc.

Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34(4):403–413CrossRefPubMed

Baker JC, Saad WRJ (2015) Common gastrointestinal symptoms do not predict the results of glucose breath testing in the evaluation of suspected small intestinal bacterial overgrowth. Am J Gastroenterol 110:S1004

Bharadwaj S, Tandon P, Gohel T, Corrigan ML, Coughlin KL, Shatnawei A et al (2015) Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. J Clin Gastroenterol 49(7):559–564. https://doi.org/10.1097/MCG.0000000000000334 CrossRefPubMed

Braun-Moscovici Y, Braun M, Khanna D, Balbir-Gurman A, Furst DE (2015) What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis? Clin Exp Rheumatol 33(4 Suppl 91):S117–S122PubMed

Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J et al (2010) Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 28 16(24):2978–2990. https://doi.org/10.3748/wjg.v16.i24.2978 CrossRefPubMedPubMedCentral

D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46(3):428–440. https://doi.org/10.1016/0002-9343(69)90044-8 CrossRefPubMed

Domsic R, Fasanella K, Bielefeldt K (2008) Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 53(5):1163–1174. https://doi.org/10.1007/s10620-007-0018-8 CrossRefPubMed

Ebert EC (2008) Gastric and enteric involvement in progressive system sclerosis. J Clin Gastroenterol 42:5–12. https://doi.org/10.1097/MCG.0b013e318042d625 CrossRefPubMed

Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C (2015) Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 27(4):481–489. https://doi.org/10.1111/nmo.12516 CrossRefPubMed

10.

Fynne L, Worsøe J, Gregersen T, Schlageter V, Laurberg S, Krogh K (2011) Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol 46(10):1187–1193. https://doi.org/10.3109/00365521.2011.603158 CrossRefPubMed

11.

Gabrielli M, D’Angelo G, Di Rienzo T, Scarpellini E, Ojetti V (2013) Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci 17(Suppl 2):30–35PubMed

12.

Gemignani L, Savarino V, Ghio M, Parodi A, Zentilin P, de Bortoli N et al (2013) Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. Semin Arthritis Rheum 42(5):522–529. https://doi.org/10.1016/j.semarthrit.2012.09.004 CrossRefPubMed

13.

Grace E, Shaw C, Whelan K, Andreyev HJN (2013) Review article: small intestinal bacterial overgrowth—prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38(7):674–688. https://doi.org/10.1111/apt.12456 CrossRefPubMed

14.

Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS (2013) Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther 37(11):1103–1111. https://doi.org/10.1111/apt.12304 CrossRefPubMedPubMedCentral

15.

Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM (1995) Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Br J Rheumatol 34(3):265–269CrossRefPubMed

16.

Khoshini R, Dai SC, Lezcano S, Pimentel M (2008) A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53(6):1443–1454. https://doi.org/10.1007/s10620-007-0065-1 CrossRefPubMed

17.

Kumar S, Singh J, Rattan S, DiMarino AJ, Cohen S, Jimenez SA (2017) Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther 45(7):883–898. https://doi.org/10.1111/apt.13963 CrossRefPubMedPubMedCentral

18.

Marie I, Ducrotté P, Denis P, Menard JF, Levesque H (2009) Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology 48(10):1314–1319. https://doi.org/10.1093/rheumatology/kep226 CrossRefPubMed

19.

Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P (2015) Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 14(6):547–554. https://doi.org/10.1016/j.autrev.2015.01.018 CrossRefPubMed

20.

Miazga A, Osiński M, Cichy W, Żaba R (2015) Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci 2015 60(1):118–124. https://doi.org/10.1016/j.advms.2014.09.001 CrossRefPubMed

21.

Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M et al (2008) Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 103:1257–1262. https://doi.org/10.1111/j.1572-0241.2007.01758.x CrossRefPubMed

22.

Rezaie A, Pimentel M, Rao SS (2016) How to test and treat small intestinal bacterial overgrowth. Curr Gastroenterol Rep 18(2):8. https://doi.org/10.1007/s11894-015-0482-9 CrossRefPubMed

23.

Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A et al (2013) Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology 52(6):1095–1100. https://doi.org/10.1093/rheumatology/kes429 CrossRefPubMed

24.

Tauber M, Avouac J, Benahmed A, Barbot L, Coustet B, Kahan A et al (2014) Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol 32(6 Suppl 86):S–S82PubMed

25.

Maguire M, Maguire G (2017) The role of microbiota, and probiotics and prebiotics in skin health. Arch Dermatol Res 309:411–421CrossRefPubMed

Title: Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature
Authors: Beata Polkowska-Pruszyńska
Agnieszka Gerkowicz
Paulina Szczepanik-Kułak
Dorota Krasowska
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 1/2019
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-018-1874-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Mortality and risk factors among Israeli bullous pemphigoid patients

Evidence of proliferative activity in human Merkel cells: implications in the histogenesis of Merkel cell carcinoma

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata

Leakage of sweat into the dermo-epidermal junction as a possible trigger for lichen planus lesion development

CXCL12 regulates differentiation of human immature melanocyte precursors as well as their migration

Podoplanin suppresses the cell adhesion of epidermal keratinocytes via functional regulation of β1-integrin